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when considering a α/β ratio of 10. The mean GTV and PTV 
D98% and D50% were 41.6Gy (SD:7.7) and 46.5Gy (SD:6.8) 
,39.3Gy (SD:7) and 46.1Gy (SD:6.6) respectively. Each 
treatment was delivered by an average of 158 beams. All 
dose constraint parameters proposed by Timmerman were 
respected (Semin.Radiat.Oncol.2008). Furthermore, the 
average difference between the Raytracing and the Monte 
Carlo algorithm was 0.43% on these values. At a median 
follow up of 30.9 months (range: 5.7-50.3), the 1 and 2-year 
LC rates remained stable at 83.5%.The 1 and 2-year liver PFS 
and the DFS rates were 57.1%, 46.1% and 75.5%, 64.4% 
respectively. The 2 year OS was 60.6% (Figure 1). No acute 
grade 2 toxicities were observed. Three patients reported 
late grade 2 gastro-intestinal toxicities. No late grade 3 nor 4 
toxicities were reported. 
 
 
 
Conclusion: Robotic SBRT is feasible, safe and very well 
tolerated for the treatment of hepatic oligometastases. Our 
outcome results compare favorably from previous published 
studies of SBRT. It could represent a valid treatment option 
in the multimodality treatment of unresectable hepatic 
oligometastases. 
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Purpose or Objective: Patients with locally advanced 
gallbladder cancer (LAGC) have a dismal prognosis. We 
investigated outcomes and risk factors for overall survival 
(OS) in patients treated with radical surgery and adyuvant 
chemoradiotherapy (CRT). 
 
Material and Methods: A total of 212 patients with LAGC 
[⩾cT3 59% and/or cN+ 52%) were studied. For survival 
outcomes potential associations were assessed in univariate 
and multivariate analyses using the Cox proportional hazards 
model. We constructed a risk scoring system in which points 
were assigned to each risk factor by dividing each ß 
coefficient in the final model by the lowest ß coefficient and 
rounding to the nearest integer. 
 
Results: Median follow-up was 46.2 months (2-235). Five-year 
OS for the entire cohort was 50.2%. In multivariate analysis 
higher pT stage [HR 1.73, p = 0.01], R1 resection [HR 5.06, p 
< 0.01], and number of surgical procedures [HR 1.41, p = 
0.05] were associated with an increased risk of death. A risk 
model was generated to determine a prognostic index for 
individual patients with LAGC. 
 
Conclusion: Overall results after multimodality treatment of 
LAGC are promising. Classification of risk factors for death 
has contributed to propose a prognostic index that could 
allow us to guide risk-adapted tailored treatment 
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Purpose or Objective: To retrospectively review the 
treatment outcome of esophageal cancer in our hospital, and 
compare the radiotherapy efficacy and toxicity of helical 
tomotherapy with step-and-shoot Intensity Modulation 
Radiation Therapy (IMRT). 
 
Material and Methods: Between 2007 and 2012, 108 
consecutive patients with locally advanced esophageal 
cancer, cT2-4N0-3M0-1, received neoadjuvant concurrent 
chemoradiotherapy (CCRT) followed by esophagectomy or 
definitive CCRT treatment course respectively. The 
radiotherapy was delivered with helical tomotherapy in 56 
patients, and with conventional IMRT in other 52 patients. 
We had evaluated outcomes with radiation dose, overall 
survival rate (OS), disease-free survival rate (DFS), and 
toxicity of radiation pneumonitis. 
 
Results: The median follow-up duration was 16 months. The 
median time of overall survival among all patients was 15 
months. The treatment modality with neoadjuvant CCRT 
followed by esophagectomy had favorable OS (47.6% : 
10.4%，p = 0.014), DFS (42.9% : 23.9%，p = 0.013), and local 
recurrence (33.3% : 50.7%，p = 0.574) comparing with 
definitive CCRT. No significant difference outcome of OS was 
found between tomotherapy and conventional IMRT. The 
patients using tomotherapy had less incidence and severity of 
radiation pneumonitis (only one patient with less than grade 
3 radiation pneumonitis in tomotherapy group; 5 patients < 
grade 3 and 2 patients > grade 3 radiation pneumonitis in 
conventional IMRT group). 
 
Conclusion: In our study, the treatment outcomes of 
neoadjuvant CCRT followed by esophagectomy for esophageal 
cancer are better in OS, DFS, and local control than 
definitive CCRT. Tomotherapy may reduce lung dose, and 
probably reduce incidence and severity of radiation 
pneumonitis when compared with conventional IMRT. 
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Purpose or Objective: To evaluate the feasibility and 
efficacy of Stereotactic Ablative Body Radiotherapy (SABR) in 
the treatment of liver metastases from radioresistant primary 
tumors. 
 
Material and Methods: Patients with inoperable liver 
metastases from renal cancers, melanoma and sarcomas, not 
amenable to other locoregional therapies, treated with SABR 
were included in this retrospective study. Inclusion criteria 
were: Karnofsky Performance Status of 70; no evidence of 
progressive or untreated gross disease outside the liver; 
maximum tumor diameter less than 6 cm; no more than 3 
liver lesions; normal liver volume greater than 1000 cm3; 
adequate liver function. Dose prescription ranged from 75 to 
50.26Gy in 3 consecutive fractions, delivered with RapidArc 
VMAT, with 10MV FFF photons. Local control was defined 
according to RECIST criteria.Toxicity was classified according 
to the Common Toxicity Criteria (CTC) version 3.0. 
 
Results: From April 2010 to October 2015, 20 patients were 
treated with SABR for a total number of 24 lesions. Median 
follow-up was 21 (range 6–58) months. In field progression 
was observed in 1 patient for a total of 2 lesions. One and 2 
